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Role of neutrophil derived oxidants and elastase in lipopolysaccharide-
mediated renal injury. Gram-negative bacterial sepsis is frequently
associated with acute renal failure but the specific effects of lipopoly-
saccharide (LPS) and other bacterial products on kidney function are
not known. Since either LPS or formyl-methionyl-leucyl-phenylalanine
(FMLP)—a chemotactic peptide from bacterial cell walls—activate
neutrophils (PMN) to release a number of potentially toxic factors in
vitro, we determined the effect of adding PMN with LPS and/or FMLP
to isolated perfused rat kidneys. Isolated rat kidneys perfused with LPS
alone or LPS and normal PMN had normal glomerular filtration rates
(GFR) and tubular Na reabsorption (TNa). Kidneys perfused with
FMLP alone or FMLP and normal PMN also had normal GFR and TNa.
In contrast, addition of PMN with both FMLP and LPS caused
progressive renal dysfunction. For example, after 60 minutes of perfu-
sion, GFR was reduced from 610 31 to 147 17 pi/min/g and TNa
from 97 1 to 72 2%, both P < 0.01. Perfusion with the 02 metabolite
scavengers catalase or dimethylthiourea afforded no protection while
perfusion with the neutrophil elastase inhibitor Eglin C conferred
substantial, but not complete, protection: GFR 492 34 sl/min/g; TNa
91 3%. However, perfusion with both Eglin C and catalase com-
pletely prevented the toxic effects of LPS and FMLP-treated PMN on
renal function. We conclude that in isolated kidneys, I) the toxic effects
of LPS requires FMLP-treated PMN and that 2) LPS and FMLP treated
PMN cause progressive renal injury which is mediated by both 02
metabolites and neutrophil elastase.
Gram-negative bacterial sepsis is frequently associated with
acute renal failure [1]. Bacterial endotoxin appears to be pivotal
in the pathogenesis of renal failure since infusion of the lipo-
polysaccharide (LPS) fraction of endotoxin (which possesses
most of the biologic activity) [21 results in marked reductions in
GFR [3]. The mechanism by which LPS results in renal
dysfunction appears to be complex, Although bacterial sepsis is
often associated with systemic hypotension, acute renal failure
can occur in the absence of changes in systemic hemodynamics
[3—5]. A number of additional factors have been implicated to
account for reductions in GFR. These include renal nerves,
hormones such as angiotensin II and norepinephrine [3, 6],
eicosanoids [3, 6, 7], cytokines such as tumor necrosis factor [8]
or interleukin-1 [9] and platelet activating factor [10].
LPS and other bacterial products are potent stimulators of
polymorphonuclear leukocytes (PMN) in vitro [11—141. Acti-
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vated PMN release a number of factors which are potentially
nephrooxic. These include toxic products of oxygen metabo-
lism (02 metabolites) as well as proteinases such as neutrophil
elastase and metalloproteinases [15, 16]. Despite this potential
interaction between LPS and PMN, the role of PMN in acute
renal failure associated with gram negative sepsis has not been
carefully evaluated. Moreover, while synergism between neu-
trophil elastase and oxidants has been described in other
systems [16, 171, this type of additive interaction between
neutrophil derived oxidants and proteinases has not been
described in the kidney. We undertook this study, therefore, to
determine the role of PMN in bacterial-product mediated renal
injury. To address this issue, we utilized the isolated perfused
rat kidney. In this simple system, the specific effects of PMN
activated with bacterial products-LPS and/or formyl-methionyl-
leucyl-phenylalanine (FMLP) can be determined in the absence
of circulating hormonal or other factor which would otherwise
complicate elucidation of the role of PMN. Using this strategy,
we obtained results which support the premise that bacterial
products activate PMN to injure kidneys by both 02 metabolite-
and elastase-mediated mechanisms.
Methods
Sources of reagents
The following reagents were used in this study: albumin
(fraction V bovine, Reheis Chemical, Phoenix, Arizona, USA);
hydroxyl ['4C] methyl inulin (Amersham, Arlington Heights,
Illinois, USA); dimethylthiourea (DMTU) (Alfa Products, Dan-
vers, Massachusetts, USA); phorbol myristate acetate (PMA),
catalase (CAT) (bovine liver, 2,000 U/mg protein), FMLP,
elastase (Type IV Pancreatic 70 U/mg protein (Sigma Chemical,
St. Louis, Missouri, USA); LPS (#201 Escherichia Coil 0111:
B4, List Biological Laboratory, Inc., Campbell, California,
USA); Eglin C (Ciba-Geigy, Switzerland) [17, 18].
Perfusion of isolated, rat kidneys
Perfusion of the isolated rat kidney was conducted according
to Nishiitsutsuji-Uwo, Ross and Krebs [19] as modified by
Little and Cohen [20] and previously described in our labora-
tory [21]. Briefly, after the right renal artery was cannulated,
the kidney was transferred to a perfusion chamber and perfused
using a pulsatile pump at a constant mean arterial pressure
(distal to the tip of the cannula) of 100 mm Hg. Following a
15-minute equilibration period, three urine collections and
perfusion samples were obtained at 15 minute intervals. Perfu-
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Fig. 1. Effect of addition of neutrophils (PMN N = 5),
chemotactic peptide (FMLP, N = 5) or lipopolysaccharide(LPS, N = 6) on the function of isolated perfused kidneys.
Data are presented after 60 minutes of perfusion. Grey area
denotes mean value SEM (N = 10) for kidneys perfused
without additions (control kidneys).
sion samples were placed in a test tube for subsequent deter-
minations of sodium and [14C] inulin. Each perfusion lasted for
60 minutes. Urine and perfusate samples were stored at —20°C
within 60 minutes of collection. For each perfusion, 150 ml of a
Krebs-Ringer bicarbonate solution was used that contained
urea, (hydroxyl ['4C1 methyl) inulin, and albumin. The final
composition of the perfusion medium (in m unless otherwise
noted) was 140 Na, 5.0 K, 1.2 ionized Ca, 1 Mg, 105 Cl, 25
bicarbonate, 1 sulfate, I phosphate, 7 urea, 70 mg/mI albumin,
5 glucose, and I ml/l00 ml perfusate of Aminosyn 8.5% (Abbott
Laboratories, North Chicago, Illinois, USA).
Measurement of renal injury
Measurements of glomerular filtration rate (GFR), and tubu-
lar sodium reabsorption (TNa), perfusion flow rate (PFR) were
used to assess renal injury. Urinary clearances of [14C1 inulin
and sodium were calculated from their respective urine and
plasma concentration ratios. Sodium was measured with an IL
343 flame photometer (Instrumentation Laboratory, Lexington,
Massachusetts, USA). Radioactivity of ['4CJ inulin was
counted in a Packard Tricarb model 460 liquid scintillation
counter (Packard Instruments, Laguna Hills, California, USA).
Preparation of neutrophils
Neutrophils were purified from human blood anticoagulated
with sodium citrate (0.38%). Cells were separated by sedimen-
tation and centrifugation and then were resuspended in platelet-
poor plasma, diluted 1:4 with 6% dextran (Pharmacia Fine
Chemicals, Piscataway, New Jersey, USA) in saline. Erythro-
cytes were separated from leukocytes by sedimentation. The
leukocyte-rich supernatant was aspirated, underlaid with
Ficoll-Hypaque (Pharmacia Fine Chemicals), and centrifuged at
275 g to separate monocytes and neutrophils. Sedimented
neutrophils were resuspended in Hank's buffered salt solution
(HBSS) before injection into perfUsates. Final preparations
contained 94 to 96% neutrophils and 4 to 6% monocytes.
Preparation of phorbol myristate acetate (PMA)
PMA (1 2-0-tetradecanoyl-phorbol- 13-acetate) was dissolved
in dimethylsulfoxide at 5 mg/mI and divided into 200 g aliquots
that were frozen at —70°C. Just before use, aliquots were
thawed and diluted to 200 g/ml in normal saline.
Our investigations consisted of four protocols:
Protocol I was designed to determine the effects of LPS,
PMN and FMLP on isolated kidney function. Isolated kidneys
were perfused with LPS (1 g/m1, N = 6), PMN (3 x io
cells/mi, N = 5) or FMLP (1 x 106 M; N = 5). These
concentrations were chosen because in preliminary studies, we
determined that this combination of agents resulted in a very
reproducible model of renal injury. PMN, LPS and FMLP were
added to the perfu sate at time 0 of perfusion.
Protocol II was designed to determined whether addition of
PMN along with LPS and/or FMLP caused renal injury. For
these studies, kidneys were perfused with PMN and LPS (N =
5), PMN and FMLP (N = 5), or PMN plus LPS and FMLP (N
= 7). In other studies, kidneys were perfused with LPS and
FMLP without PMN (N = 3).
Protocol III was designed to determine the role of 02 metab-
olite scavengers in kidneys exposed to PMN plus LPS and
FMLP. Isolated kidneys were exposed to PMN plus LPS and
FMLP in the presence of no additions (N = 5) or DMTU (15
mM, N = 6) or CAT (200 U/ml, N 6).
Protocol IV was designed to determine the contribution of
neutrophil elastase to injury in kidneys exposed to PMN plus
LPS and FMLP. For these studies, the non-oxidizable neutro-
phil elastase inhibitor Eglin C [17, 181 was utilized. To deter-
mine the specificity of Eglin C, kidneys were perfused with
elastase (2.8 U/ml, N = 3 and 5.6 U/mI, N = 4), or elastase and
Egiin C (2 MM) together (N = 6) or elastase plus CAT (N = 4)
or elastase plus DMTU (N = 4). In additional studies, kidneys
were exposed to PMN with PMA (10 ng!ml) in the presence of
no additions (N = 5), Eglin C (N = 5) or CAT (N = 6). In the
final group of perfusions, isolated kidneys were exposed to
PMN plus LPS and FMLP with no additions (N = 6) or Eglin C
(N = 6) or Eglin C plus CAT (N = 6).
Statistical analyses
Statistical analyses were performed using one-way analysis
of variance in conjunction with Scheffe's-test for comparison of
multiple means. A P value of < 0.05 was considered significant.
Data were expressed as means SEM.
Results
Figure 1 shows the effect of addition of PMN, LPS or FMLP
to isolated perfused kidneys. During the 60 minutes of perfu-
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sion, there were no effects attributable to addition of PMN, LPS
or FMLP alone on GFR, TNa or PFR (data not shown).
Figure 2 shows the effects of addition of PMN with LPS
and/or FMLP on renal function. Kidneys exposed to PMN and
either LPS or FMLP did not have decreases in GFR, TNa or
PFR (data not shown). In contrast, there were time-dependent,
progressive decreases in GFR and TNa (but not PFR) in kidneys
exposed to PMN along with both LPS and FMLP. For example,
after 60 minutes of perfusion, GFR was reduced to 147 17
4lmin/g and TNa 72 2% (both P < 0.01) in kidneys exposed
to PMN plus LPS and FMLP compared to kidneys exposed to
PMN and FMLP (610 31 d/min/g and 98 1%) or PMN and
LPS (655 25 pi/min/g and 97 1%). Addition of LPS and
FMLP without PMN did not result in decreases in GFR (593
26 pi/minlg) or TNa (97 2%).
To determine if decreases in renal function in kidneys ex-
posed in PMN in the presence of LPS and FMLP were caused
by 02 metabolites, 02 metabolite scavengers, catalase or
DMTU, were included in the perfusate. In earlier studies, we
found that the concentrations of CAT and DMTU used in these
studies prevented renal dysfunction caused by PMN stimulated
with PMA, a known agonist of 02 metabolite release by PMN
[221. Figure 3 shows that either CAT or DMTU resulted in
small, but statistically insignificant, increases in both GFR and
TNa compared to kidneys perfused without additions. Addition
Fig. 3. Effect of no additions ,N = 5), addition of
catalase (U, CAT, N = 6) or dimethylthiourea (A, DMTU,N = 6) on kidneys perfused with PMN, LPS and FMLP.
Grey area denotes mean value SEM (N = 10) for control
kidneys.
of CAT or DMTU alone during perfusion did not alter kidney
function.
To determine whether neutrophil elastase mediated de-
creases in renal function in kidneys perfused with PMN treated
with LPS and FMLP, studies were performed with the potent
non-oxidizable neutrophil elastase inhibitor, Eglin C [17, 18].
Figure 4 shows the effect of elastase on isolated kidney func-
tion. Perfusion with elastase caused time and concentration
dependent decreases in GFR and TNa (but not PFR, data not
shown). For example, during perfusion with elastase (5.6 U/mI),
GFR was 443 23, 318 24 and 221 22 .d/min/g after 30, 45
and 60 minutes of perfusion, respectively. Elastase mediated
renal injury was prevented by co-addition of Eglin C but not by
the 02 metabolite scavengers CAT or DMTU. Addition of Eglin
C alone during perfusion did not alter the function of isolated
kidneys.
Figure 5 addresses the specificity of Eglin C treatment in
kidneys perfused with PMN and PMA. Under these conditions,
renal injury was prevented by addition of catalase but not Eglin
C. These results indicate that Eglin C prevents elastase, but not
02 metabolite effects on isolated kidneys.
Figure 6 demonstrates the effect of Eglin C in kidneys
exposed to PMN added with LPS and FMLP. Compared to no
additions, perfusion with Eglin C caused increases in GFR and
TNa which exceeded values in kidneys perfused with PMN,
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Fig. 4. Effect of no additions or addition of Eglin
C, (N = 4) or catalase (CAT, N = 4) or
dimethylthiourea (DMTU, N = 4) on renal injury
caused by low (2.8 U/mI) and high (5.6 U/mi)
concentrations of elastase. Results are presented
after 60 minutes of perfusion, *p < 0.01
compared to elastase alone. Grey area denotes
mean value SEM (N = 10) for control kidneys.
Fig. 5. Effect of no additions (N = 5), addition of catalase
(CAT, N = 6), or Eglin C (N = 5) on kidneys perfused with
phorbol myristate acetate (PMA) and PMN. Results are
presented after 60 minutes of perfusion. Grey area denotes
mean value SEM (N = 10) for control kidneys.
0.01 compared to PMA and PMN.
Fig. 6. Effect of no additions (S. N = 6), addition of Eglin
C (•, N 6) or Eglin C and CAT (A, N = 6) on kidney
perfused with PMN, LPS and FMLP. Grey area denotes
mean value SEM (N = 10) for control kidneys. * D
0.05 vs. Eglin C, P < 0.01 vs. Eglin C plus CAT. ** P <
0.01 vs. Eglin C and Eglin C plus CAT. P = NS vs.
Eglin C, P < 0.05 vs. Eglin C plus CAT
LPS and FMLP but did not reach control values. To determine
whether 02 metabolites contributed to residual decreases in
renal function in kidneys perfused with Eglin C, CAT was
included with Eglin C. The figure demonstrates that compared
to no additions, perfusion with Eglin C and CAT normalized
GFR and TNa measurements in kidneys perfused with PMN,
LPS and FMLP.
Discussion
Systemic administration of LPS causes renal dysfunction in
vivo by unknown mechanisms which could include alterations
in systemic or renal hemodynamics [3—51, activation of renal
nerves [3] or alterations in circulating hormones and cytokines
[3, 5—10]. We used the isolated perfused kidney so that we could
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determine the specific effects of LPS in a relatively simple test
system. As has also recently been reported by Cohen, Black
and Wertheim [23], we found that addition of LPS had no
adverse effect on renal function. Only when LPS was added
with FMLP-treated PMN did injury develop in the isolated
perfused kidney.
In earlier studies [22] and other [24, 251 have shown that
PMN stimulated with a single agent such as PMA cause renal
injury. In the current studies we were not able to demonstrate
deleterious effects of LPS or FMLP and PMN. However,
concentrations of LPS, which by themselves or with PMN did
not injure kidneys, appeared to enhance the injurious effect of
FMLP-treated PMN. A similar phenomenon is observed in
vitro. Under these conditions, LPS appears to enhance the
release of a number of PMN products. For example, concen-
trations of LPS which do not cause oxidant or leukotriene B4
release, enhance the effect of formyl peptides to cause super-
oxide release [11] and zymogen to cause leukotriene B4 release
from PMN [26]. Although the precise mechanism of PMN
priming is not known, recent studies suggest that increases in
cytosolic calcium are an important mediator of LPS priming of
PMN for an enhanced superoxide release [27].
The model used in the current studies may be relevant to
clinical sepsis. In this regard, in gram negative sepsis circulating
PMN are exposed to low concentrations of multiple PMN
activators including LPS and chemotactic peptides. Whereas
neither agonist circulates in concentrations sufficient to activate
PMN, Henson et al have shown that incubation of PMN with
LPS results in enhanced release of both oxidants and neutrophil
elastase in response to concentrations of a second agonist
which when administered alone, do not activate PMN [11, 13,
281. Our results in the isolated perfused kidney are consistent
with the data of Henson et al [11, 13, 28] and indicate that
LPS-mediated renal injury requires FMLP-activated PMN.
Although our data reveal an important role for PMN in
LPS-mediated renal injury, other circulating leukocytes may
also contribute to LPS injury. For example LPS stimulates
monocytes to release a variety of biologically active cytokines
such as tumor necrosis factor [29, 30], which have been
proposed to mediate many of the responses associated with
endotoxemia [31].
In addition our data imply that LPS injury is mediated by the
effects of LPS on PMN rather than on kidney tissue. However,
the possibility that LPS interacted with kidney tissue to acti-
vated PMN cannot be completely excluded since other PMN
activators directly injure epithelial cells and endothelial cells
[32—34]. In this scheme, LPS would injure epithelial and/or
mesangial cells making them susceptible to PMN. Although we
cannot exclude a subtle effect of LPS or FMLP on the kidney,
our results underscore the critical importance of PMN in this
model of renal failure since addition of LPS or FMLP in
combination with PMN did not result in renal injury. Renal
injury only occurred when PMN were exposed to both LPS and
FMLP.
Activated PMN release a number of products which could
potentially injure kidneys. Neutrophil derived toxins include 02
metabolites, myeloperoxidase and proteinases, such as neutro-
phil elastase and metalloproteinases [15, 16]. 02 metabolites
from PMN can injure kidneys directly [351 and activate latent
metalloproteinases which can injure kidneys [241. Myeloperox-
idase can interact with circulating halides and hydrogen perox-
ide to cause marked increases in glomerular protein excretion
[36]. Neutrophil elastase appears to be an important mediator of
lung injury especially in settings where alpha-l-antiprotease
inhibitors have been inactivated. For example, perfusion of
isolated lungs with purified neutrophil elastase increased lung
permeability but only after addition of H202 to reduce anti-
elastolytic activity [37]. Our data suggest that neutrophil
elastase can now be added to the list of PMN products which
are capable of causing glomerular and tubular dysfunction since
perfusion with the specific neutrophil elastase inhibitor Eglin C
partially prevented LPS/FMLP/PMN-induced renal injury.
Depending on the selectively of the stimulus used to activate
PMN, the role of oxidants, myeloperoxidase and proteinases in
renal injury may vary. For example, PMA is a relatively good
stimulator of 02 metabolite release compared to its effect on
proteinase release [13]. By comparison, FMLP is a relatively
potent stimulus for degranulation compared to its ability to
initiate 02 metabolite generation by PMN [13, 281. LPS/FMLP,
in the concentrations use in our study, appears to release both
02 metabolites and neutrophil elastase. Thus injury stimulated
by PMA may be more susceptible to 02 metabolite scavengers
(Fig. 5) while injury caused by LPS/FMLP (Fig. 6) appears to
require both 02 metabolite and neutrophil elastase inhibitors for
reversal.
Although both 02 metabolites and neutrophil elastase ap-
peared to contribute to LPS/FMLP and PMN mediated renal
injury, the toxic effects of LPS/FMLP/PMN on renal function
could not be totally reversed by addition of either the neutrophil
elastase inhibitor or oxygen metabolite scavengers alone. In-
stead, perfusion with both 02 metabolite scavengers and the
neutrophil elastase inhibition was required to prevent LPS/
PMN renal injury. 02 metabolites and neutrophil elastase could
interact to cause renal injury in several ways. Shah has shown
that 02 metabolites activate latent metalloproteinases to cause
glomerular basement membrane degradation [24]. This would
not seem to be an important effect of 02 metabolites on
neutrophil elastase since this enzyme is released in an active
form and does not require further modification for function.
Alternatively, 02 metabolites might enhance the action of
neutrophil elastase by inactivating circulating antiproteinases
116, 37]. The major anti-elastolytic activities in serum are a1
proteinase inhibitor and a2 macroglobulin. Both of these com-
pounds are susceptible to oxidant induced inhibition of action
[16]. Thus 02 metabolites produced by PMN inactivate protec-
tive antielastolytic activities so that the toxic effect of neutro-
phil elastase is enhanced [16, 37].
In earlier studies we showed that 02 metabolites generated by
xanthine oxidase caused injury in reperfused ischemic kidneys
[38]. Additionally, we showed that normal PMN worsened
reperfusion injury by an 02 metabolite mediated mechanism
[23], The current studies expand on the possible role of 02
metabolites and suggest a possible interaction between 02
metabolites produced by ischemic kidneys and PMN activated
with LPS. 02 metabolites produced by kidneys during reperfu-
sion could enhance the deleterious effects of neutrophil elastase
in much the same way in which 02 metabolites produced by
LPS/FMLP-activated PMN enhance neutrophil elastase-medi-
ated injury. This interaction may be particularly relevant to the
clinical observation that renal ischemia predisposes to further
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renal injury in many situations, including gram-negative bacte-
rial sepsis.
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